Wall Street Banks Eye a $600 Million Payday on CVS, Aetna Deal
(Bloomberg) -- Wall Street banks including Barclays, Goldman Sachs and Bank of America could share in a fee bonanza of as much as $600 million, after pledging one of the biggest financing checks ever to help fund CVS's $67.5 billion takeover of Aetna.
The companies are set to shell out fees for M&A advisory, financing and also arranging a bond sale next year to replace a $40 billion bridge loan from the three banks. Banks providing that loan could split up to $150 million, while underwriters on any debt sale could extract around $200 million combined, according to Freeman Consulting Services. The M&A advisers could net as much as $250 million in total, the firm estimated.
“This is very big for the banks with year-end coming up,” said Jeff Nassof, a director at Freeman. And a deal that's financed with debt is more lucrative, he said, because banks can earn fees on extending a bridge loan, then on arranging a bond sale and also in the subsequent trading of the bonds. That's on top of M&A advisory fees.
Bridge Loan
Barclays Plc, Goldman Sachs Group Inc. and Bank of America Corp. have committed to lend $49 billion for the transaction, with term loans augmenting bridge financing, a type of temporary funding.
The financing usurps the previous biggest bridge for a U.S. buyer in 2017 -- a $15.7 billion loan that Citigroup Inc. set up for medical devices provider Becton, Dickinson & Co. in April for its acquisition of C.R. Bard Inc., according to Freeman Consulting.
Other notable loans funding acquisitions include Anheuser-Busch InBev NV's $75 billion of loans for its acquisition of SABMiller Plc in 2015 and the $61 billion loan Verizon Communications Inc. secured in 2013 for its buyout of the stake in Verizon Wireless it didn't own. JPMorgan Chase & Co. and Bank of America last year promised a $40 billion loan for AT&T Inc.'s planned takeover of Time Warner Inc., a deal that anti-trust lawyers at the U.S. Justice Department are looking to block.
Barclays and Goldman Sachs served as advisers for the acquisition for CVS Health Corp., as well as providing commitments for financing in addition to Bank of America. Centerview Partners also provided financial advice to the CVS directors. Lazard and Allen & Co. LLC advised Aetna Inc. and Evercore helped the insurer's directors.
The companies are also going to be shelling out fees to lawyers, with Shearman & Sterling, Dechert, McDermott Will & Emery advising CVS and Davis Polk & Wardwell assisting Aetna.
--With assistance from Lara Wieczezynski Claire Boston and Jacqueline Poh
To contact the reporter on this story: Nabila Ahmed in New York at nahmed54@bloomberg.net.
To contact the editors responsible for this story: Shannon D. Harrington at sharrington6@bloomberg.net, Dan Wilchins
©2017 Bloomberg L.P.
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
-
When Everyone Has AI, What Gives You An Edge?
India's young workforce is entering an uncertain world of work where powerful AI tools are becoming widely accessible. The advantage will belong to those who combine deep expertise with digital fluency, and the distinctly human capabilities that technology cannot manufacture.
-
Wrong Labels, High Pesticide Residues Holding Back Agri Exports | The Reason Why
India needs stronger domestic food-safety and labelling standards, with best practices becoming part of everyday business for farmers, traders and food companies.